Extended-release and enteric-coated acetylsalicylic acid: pharmacokinetic and pharmacodynamic considerations and clinical aspects for antiplatelet therapy (review)

Dunaieva I.P.,Kryvoshapka O.V.,Shapoval O.M.,Doroshenko O.M.,Pautina O.I.,Chorna N.S.

Main
Publications
Extended-release and enteric-coated acetylsalicylic acid: pharmacokinetic and pharmacodynamic considerations and clinical aspects for antiplatelet therapy (review)

January 30, 2026

Cardiology, Rheumatology

УДК: 616.1+612.13

DOI: 10.32471/umj.1680-3051.272877

Keywords :

acetylsalicylic acid,

antiplatelet therapy,

Specialities :

Cardiology, Rheumatology

Pharmacology

Resume

Acetylsalicylic acid (ASA) remains the mainstay antiplatelet agent for the prevention of cardiovascular events. At the same time, in patients at high cardiovascular risk, reduced responsiveness to low-dose ASA is increasingly reported, which is associated with increased platelet turnover and specific pharmacokinetic features of the drug. Therefore, extended-release and enteric-coated ASA formulations have been developed to optimise antiplatelet efficacy and improve tolerability. This review summarises current evidence on the pharmacodynamics and pharmacokinetics of immediate-release and extended-release ASA formulations and analyses their clinical relevance. The available data indicate that extended-release ASA does not provide greater sustained inhibition of thromboxane A₂ than immediate-release formulations, limiting its potential advantages in patients at high cardiovascular risk.

References

1. Mazzone P.M., Spagnolo M., Capodanno D. (2024) Antithrombotic Therapy in Patients with Chronic Coronary Syndromes. Interv. Cardiol. Clin., 13(4): 493–505.
2. Sammut M.A., Storey R.F. (2024) Antithrombotic therapy in patients with atrial fibrillation after percutaneous coronary intervention. Expert Rev. Cardiovasc. Ther., 22(9): 471–482. doi: 10.1080/14779072.2024.2388265.
3. Ajjan R.A., Kietsiriroje N., Badimon L. et al. (2021) Antithrombotic therapy in diabetes: which, when, and for how long? Eur. Heart J., 42(23): 2235–2259.
4. Rivera-Caravaca J.M., Camelo-Castillo A., Ramírez-Macías I. et al. (2021) Antithrombotic Therapy in Patients with Peripheral Artery Disease: A Focused Review on Oral Anticoagulation. Int. J. Mol. Sci., 22(13): 7113. doi: 10.3390/ijms22137113.
5. Talasaz A.H., Sadeghipour P., Ortega-Paz L. et al. (2024) Optimizing antithrombotic therapy in patients with coexisting cardiovascular and gastrointestinal disease. Nat. Rev. Cardiol., 21(8): 574–592. doi: 10.1038/s41569-024-01003-3.
6. Miklík R., Jiravský O. (2022) Kyselina acetylsalicylová v primární prevenci kardiovaskulárních onemocnění. [Acetylsalicylic acid in primary prevention of cardiovascular disease]. Vnitr. Lek., 68(4): 240–245. Czech.
7. Fijałkowski Ł., Skubiszewska M., Grześk G. et al. (2022) Acetylsalicylic Acid-Primus Inter Pares in Pharmacology. Molecules, 27(23): 8412.
8. Liu S., Eckstein J., Lam A., Cheema A.N. (2023) Acetylsalicylic Acid (Aspirin) for Primary Prevention of Cardiovascular Events in Patients with Diabetes: A Systematic Review and Meta-Analysis of Randomised Controlled Trials. Curr. Vasc. Pharmacol., 21(2): 111–119. doi: 10.2174/1570161121666230131120544.
9. Scavone M., Podda G.M., Bossi E. et al. (2022) Acetylsalicylic acid in essential thrombocythemia. Wien Klin. Wochenschr., 134(1–2): 89–90.
10. Gelbenegger G., Jilma B. (2022) Clinical pharmacology of antiplatelet drugs. Expert Rev. Clin. Pharmacol., 15(10): 1177–1197. doi: 10.1080/17512433.2022.2121702.
11. Hida N., Yamazaki T., Fujita Y. et al. (2023) A Study on Pharmacokinetics of Acetylsalicylic Acid Mini-Tablets in Healthy Adult Males-Comparison with the Powder Formulation. Pharmaceutics, 15(8): 2079. doi: 10.3390/pharmaceutics15082079.
12. Marino M., Jamal Z., Zito P.M. (2023) Pharmacodynamics. In: StatPearls. Treasure Island (FL): StatPearls Publ.
13. Yang J., Yamashita-Kanemaru Y., Morris B.I. et al. (2025) Aspirin prevents metastasis by limiting platelet TXA2 suppression of T cell immunity. Nature, 640(8060): 1052–1061. doi: 10.1038/s41586-025-08626-7.
14. Bruno A., Tacconelli S., Contursi A. (2023) Cyclooxygenases and platelet functions. Adv. Pharmacol., 97: 133–165. doi: 10.1016/bs.apha.2022.12.001.
15. Szczuko M., Kozioł I., Kotlęga D. (2021) The Role of Thromboxane in the Course and Treatment of Ischemic Stroke: Review. Int. J. Mol. Sci., 22(21): 11644.
16. Cattaneo M. (2023) Aspirin in essential thrombocythemia. For whom? What formulation? What regimen? Haematologica, 108(6): 1487–1499.
17. Clerici B., Cattaneo M. (2023) Pharmacological Efficacy and Gastrointestinal Safety of Different Aspirin Formulations for Cardiovascular Prevention: A Narrative Review. J. Cardiovasc. Dev. Dis., 10(4): 137. doi: 10.3390/jcdd10040137.
18. Muataz Ali H., Schanze N., Schommer N. et al. (2021) Reticulated Platelets — Which Functions Have Been Established by In Vivo and In Vitro Data? Cells, 10(5): 1172.
19. Gragnano F., Cao D., Pirondini L. et al.; PANTHER Collaboration (2023) P2Y12 Inhibitor or Aspirin Monotherapy for Secondary Prevention of Coronary Events. J. Am. Coll. Cardiol., 82(2): 89–105. doi: 10.1016/j.jacc.2023.04.051.
20. Drugs and Lactation Database (LactMed®) (2006) Bethesda (MD): National Institute of Child Health and Human Development. Aspirin.
21. Gassanov N., Eicke M., Er F. (2021) Stellenwert der ASS-Therapie in der kardio- und zerebrovaskulären Prävention [Aspirin in primary prevention of cardiovascular and cerebrovascular diseases]. Dtsch Med. Wochenschr., 146(20): 1353–1359. German.
22. Szczuko M., Kozioł I., Kotlęga D. et al. (2021) The Role of Thromboxane in the Course and Treatment of Ischemic Stroke: Review. Int. J. Mol. Sci., 22(21): 11644.
23. Patrono C. (2023) Fifty years with aspirin and platelets. Br. J. Pharmacol., 180(1): 25–43. doi: 10.1111/bph.15966.
24. Santos-Gallego C.G., Badimon J. (2021) Overview of Aspirin and Platelet Biology. Am J Cardiol., 144 (Suppl. 1): S2–S9. doi: 10.1016/j.amjcard.2020.12.018.
25. Grimaldi S., Migliorini P., Puxeddu I. et al. (2024) Aspirin hypersensitivity: a practical guide for cardiologists. Eur. Heart J., 45(19): 1716–1726.
26. Silva G.F.D., Lopes B.M., Moser V., Ferreira L.E. (2023) Impact of pharmacogenetics on aspirin resistance: a systematic review. Arq. Neuropsiquiatr., 81(1): 62–73.
27. Van Oosterom N., Barras M., Cottrell N., Bird R. (2022) Platelet Function Assays for the Diagnosis of Aspirin Resistance. Platelets, 33(3): 329–338.
28. Sibbing D., Lavalle Cobo A.M. et al. (2025) Why low-dose aspirin remains an important antiplatelet in the management of chronic coronary syndromes. Expert Rev. Cardiovasc. Ther., 23(5): 187–195. doi: 10.1080/14779072.2025.2505439.
29. Parbon P., Kashfia J., Sadia Ch. (2020) Preparation and evaluation of Naproxen Sodium sustained release enteric coated tablets using Methocel K15M CR and Instacoat EN-II. doi: 10.13140/RG.2.2.20647.16802.
30. Hybiak J., Broniarek I., Kiryczyński G. et al. (2020) Aspirin and its pleiotropic application. Eur. J. Pharmacol., 866: 172762. doi: 10.1016/j.ejphar.2019.172762.
31. Kosinski P., Sarzynska-Nowacka U., Fiolna M., Wielgos M. (2018) The practical use of acetylsalicylic acid in the era of the ASPRE trial. Update and literature review. Ginekol. Pol., 89(2): 107–111. doi: 10.5603/GP.a2018.0018.
32. Visagie J.L., Aruwajoye G.S., van der Sluis R. (2024) Pharmacokinetics of aspirin: evaluating shortcomings in the literature. Expert Opinion on Drug Metabolism & Toxicology, 20(8): 727–740. doi.org/10.1080/17425255.2024.2386368.
33. Guo J., Wang J., Feng J. (2019) Aspirin resistance mediated by oxidative stress-induced 8-Isoprostaglandin F2. J. Clin. Pharm. Ther., 44(5): 823–828.Lim J., Song Y., Jang J.H. et al. (2018) Aspirin-inspired acetyl-donating HDACs inhibitors. Arch. Pharm. Res., 41(10): 967–976. doi: 10.1007/s12272-018-1045-z.
34. Du G., Lin Q., Wang J. (2016) A brief review on the mechanisms of aspirin resistance. Int J Cardiol., 220: 21–26. doi: 10.1016/j.ijcard.2016.06.104.